What Are the Side Effects of a Pain Pump?

Pain pumps, formally known as intrathecal drug delivery systems, deliver medication directly into the fluid surrounding the spinal cord through a surgically implanted device and catheter. Their side effects range from common nuisances like headaches and itching to rare but serious complications including infection, spinal cord compression, and breathing problems. Because the device sits inside the body and involves both surgical hardware and potent drugs, the side-effect profile is broader than most people expect, touching surgery-related risks, drug-specific reactions, hormonal changes, and mechanical failures of the device itself.

Headaches and Spinal Fluid Leaks After Surgery

The most frequent complaint in the days and weeks after a pain pump is implanted is a headache caused by leaking cerebrospinal fluid (CSF) at the site where the catheter enters the spinal canal. This is essentially the same phenomenon as a spinal-tap headache: the puncture allows fluid to seep out, which lowers pressure around the brain and produces pain that worsens when you sit or stand up. One retrospective study found that roughly a third of patients who did not receive a preventive sealant developed these headaches, while applying fibrin glue during surgery cut the rate to about 11%.¹ In a larger pediatric series looking at over 300 procedures, about 16% showed evidence of a CSF leak, with headaches being the dominant symptom.²

Not every CSF leak announces itself with a classic headache. One case report described a patient whose leak presented as lower-back pain, leg nerve pain, and a fluid collection under the skin near the surgical site, with the typical headache only showing up days later.³ This matters because an unusual presentation can delay diagnosis if no one is looking for it. In patients who cannot report symptoms verbally, such as children with cerebral palsy, changes in behavior or posture may be the only clue that something is wrong.² Most CSF leaks resolve with conservative treatment or an epidural blood patch, though some require a catheter replacement.

Infection

Any implanted device carries an infection risk, and pain pumps are no exception. Reported infection rates in published case series generally land between about 6% and 9% of patients. In one multicenter study of over 300 patients receiving intrathecal baclofen, roughly 6% developed infections, most involving skin bacteria like Staphylococcus species.⁴ A separate review of 218 patients at a single center found surgical-site infections in about 6% and meningitis in about 2%, with every case of meningitis preceded by a deeper wound infection.⁵

Signs of infection include redness, warmth, and swelling around the pump pocket or along the catheter track, and sometimes fever. The concern is that a surface infection can travel along the catheter into the spinal canal and cause meningitis, which is why early treatment with antibiotics matters. In stubborn cases, the pump may need to be removed entirely to clear the infection, then reimplanted later.

Spinal Hematoma

Bleeding inside the spinal canal after catheter placement is rare but can have serious consequences, including nerve damage. An analysis of the FDA’s adverse-event database documented a case in which a spinal epidural hematoma formed a week after implant surgery, ultimately contributing to the patient’s death because the blood collection compressed the catheter and spinal cord.⁶ The risk is substantially higher for people taking blood thinners. Estimates from the broader epidural-anesthesia literature put the background rate of spinal hematoma at roughly 1 in 168,000 procedures, rising to around 1 in 3,100 when low-molecular-weight heparins are involved.⁷ For this reason, anticoagulant medications are typically held before and after implantation under careful medical guidance.

Opioid-Related Side Effects

Most pain pumps deliver an opioid, usually morphine or hydromorphone, directly into the spinal fluid. Even though the doses are far smaller than what you would take by mouth, opioids delivered this way still produce recognizable opioid side effects. In one clinical series, the most common complaints were difficulty urinating and itching.⁸ Nausea and constipation also occur, though often less severely than with oral opioids, because the total amount of drug circulating through the rest of the body is lower.⁹

The side effect that concerns doctors most is respiratory depression, a slowing or shallowing of breathing that can become life-threatening. A systematic review of serious adverse events after intrathecal morphine found that respiratory depression combined with excessive sleepiness was the dominant pattern, typically appearing within 2 to 24 hours after dosing. Life-threatening breathing problems were most common at higher doses or when other sedating medications were used at the same time.¹⁰ Research has shown that intrathecal morphine dulls the body’s normal breathing response to low oxygen levels, and this effect lasts longer than it does with an equivalent dose given intravenously.¹¹ This is why close monitoring is standard after the initial implant and during dose increases.

Hormonal Disruption and Bone Health

One of the less well-known long-term effects of intrathecal opioids is suppression of the hormonal system. Opioids act on the brain’s hypothalamus and pituitary gland to reduce production of sex hormones. A study measuring hormone levels in patients on intrathecal morphine found that both men and women showed signs of hypogonadism, with low testosterone or estrogen and low levels of the pituitary hormones that normally stimulate their production. Control subjects of the same sex and age had normal levels. Two men in the study saw their hormones recover after the intrathecal opioid was stopped.¹² A separate case report documented suppression of multiple pituitary hormones at once, and the dysfunction persisted even after switching from the intrathecal pump to oral opioids.¹³

The practical consequences extend beyond low libido and fatigue. Chronic hypogonadism from opioid therapy is linked to reduced bone density, which raises fracture risk. Researchers have identified three routes through which opioids may weaken bones: sedation and dizziness increasing fall risk, a direct effect of opioids on bone-building cells, and the hormonal suppression just described.¹⁴ Studies of patients on long-term intrathecal opioid therapy specifically have found associations between low sex hormones and low bone-mineral density.¹⁵ If you have a pain pump delivering opioids, periodic blood work to check hormone levels and bone-density scans are reasonable steps to discuss with your doctor, though not every clinic routinely offers them.

Granuloma Formation at the Catheter Tip

Over months or years of use, some patients develop an inflammatory mass, called a granuloma, at the tip of the catheter inside the spinal canal. This is not an infection or a tumor. It is an abnormal tissue growth triggered by the concentrated drug bathing the same spot of spinal tissue day after day. Granulomas are most strongly associated with morphine, and their formation correlates with higher drug doses and concentrations.¹⁶

A small granuloma may cause no symptoms at all and only be found incidentally on imaging. A larger one can compress the spinal cord or nerve roots, producing worsening back pain, numbness, tingling, or weakness in the legs. In a case series of four patients, each developed a mass at the catheter tip that caused increased pain and declining neurological function.¹⁷ Another case involved a woman who had been on intrathecal morphine for 20 years before developing a granuloma that compressed her spinal cord, causing sensory changes in both legs.¹⁸

The warning sign to watch for is a gradual loss of pain relief combined with new neurological symptoms, especially if increasing the dose does not help or makes things worse. Treatment typically involves stopping the offending drug, sometimes switching to an alternative medication, and occasionally surgically removing the granuloma if spinal cord compression is severe.

Side Effects Specific to Non-Opioid Medications

Pain pumps do not always deliver opioids. Depending on the condition being treated, the pump may infuse baclofen for spasticity, ziconotide for chronic pain, bupivacaine as a local anesthetic, or combinations of these drugs. Each carries its own side-effect profile.

Ziconotide

Ziconotide, derived from a marine snail toxin, is one of the few non-opioid options approved for intrathecal pain management. Its side effects are predominantly neuropsychiatric. Patients may develop confusion, memory problems, hallucinations, or mood changes. In one reported case, a man with no prior psychiatric history developed command auditory hallucinations within 24 hours of a dose increase, after having used ziconotide for several years without incident.¹⁹ These symptoms typically resolve after the drug is stopped, but they can be frightening for patients and families, especially when they appear suddenly. Close monitoring during dose adjustments is standard practice.

Baclofen

Baclofen delivered intrathecally is highly effective for severe spasticity, but the drug’s most dangerous side effect is not really about the drug itself. It is about what happens when delivery suddenly stops. Baclofen withdrawal syndrome, triggered by abrupt cessation, can cause altered mental status, high fever, fast heart rate, blood pressure swings, seizures, and rebound spasticity severe enough to resemble the rigidity seen in certain medical emergencies.²⁰ The syndrome can mimic sepsis closely enough to mislead emergency physicians who are not familiar with it.²¹ Withdrawal can be triggered by an empty reservoir, a catheter kink, a pump malfunction, or a missed refill appointment. Patients with baclofen pumps are generally advised to carry identification describing the device and to treat any refill appointment as urgent.

Bupivacaine

When the local anesthetic bupivacaine is part of the drug mix, it can produce numbness or weakness in the legs, especially after a dose change or pump refill. One case report described a patient who developed sensory nerve problems, low blood pressure, and leg weakness after a routine pump refill involving bupivacaine and morphine.²² Over the longer term, bupivacaine delivered to the thoracic spine produces a sustained drop in blood pressure. A study tracking blood pressure over a year found a significant decrease in systolic pressure at 3, 6, and 12 months, likely because the drug blocks sympathetic nerve signals that help regulate blood vessel tone.²³ For someone with already-low blood pressure, this could cause dizziness or fainting. For someone with high blood pressure, it could actually be a welcome secondary benefit, though it needs to be managed alongside any blood-pressure medications.

Hardware and Mechanical Failures

A pain pump is ultimately a piece of implanted machinery, and machinery can break. The catheter, a thin tube running from the pump to the spinal canal, can kink, migrate out of position, or in rare cases snap entirely. One case report described a catheter that fractured, leaving a nearly 29-centimeter fragment floating in the spinal canal.²⁴ The pump motor itself can stall. In one documented case, internal inspection revealed corrosion of the motor gearbox, which caused the pump to stop delivering medication intermittently over several days before the problem was fully recognized.²⁵

The consequence of any mechanical failure depends on the drug being delivered. A stalled pump delivering morphine may produce opioid withdrawal symptoms: sweating, agitation, nausea, and body aches. A stalled pump delivering baclofen can trigger the life-threatening withdrawal syndrome described above. This is why most modern pumps have alarm systems that alert the patient when something is wrong, though no alarm system is foolproof. Any unexplained return of pain or spasticity in a pump patient warrants a device check.

Risks During Routine Refills

Pain pumps need periodic refills, typically every one to six months depending on the drug concentration and flow rate. The refill involves inserting a needle through the skin into a port on the pump reservoir. This is usually a straightforward office procedure, but it carries a specific risk called a “pocket fill,” where some or all of the medication is inadvertently injected into the tissue surrounding the pump rather than into the reservoir. A prospective study of 221 refills observed overdose symptoms after about 3% of procedures. The researchers found that a volume discrepancy above a certain threshold after the refill should raise suspicion for a pocket fill.²⁶

A pocket fill is dangerous because the medication in the refill syringe represents weeks’ or months’ worth of drug. If a concentrated opioid intended to drip slowly into the spinal canal instead absorbs rapidly through surrounding tissue, the result can be a sudden overdose. Symptoms include extreme drowsiness, slowed breathing, and dangerously low blood pressure. Refills should be performed by practitioners experienced with the specific pump model, using proper technique to confirm needle placement in the reservoir before injecting.

MRI Compatibility and Device Interactions

People with pain pumps often need MRI scans for unrelated medical issues, and the strong magnetic fields involved create specific concerns. Certain pump models have been reported to experience memory errors during MRI, and the manufacturer notes a theoretical risk of permanent motor stall if the pump is oriented at a particular angle relative to the scanner’s magnetic field, though no such case has actually been documented.²⁷ Practically speaking, this means the pump needs to be interrogated and potentially reprogrammed after an MRI to confirm it is still functioning correctly. Some older pump models are not MRI-compatible at all. If you have a pain pump and are scheduled for an MRI, the radiology team and your pain management team both need to be involved in planning the scan.

Why Symptoms Change Over Time

Something that catches many patients off guard is that side effects with a pain pump are not static. Early side effects, like post-surgical headaches and wound-site discomfort, resolve within weeks. Opioid-related issues such as itching and nausea often improve as your body adjusts to the medication. But other problems take months or years to emerge. Hormonal suppression accumulates gradually and may not produce obvious symptoms until bone density has already declined. Granulomas grow slowly. Hardware degradation from corrosion or repeated mechanical stress is a function of time. This shifting timeline means that the monitoring a pain pump requires does not end once you recover from surgery. Regular follow-up, including device interrogation, refills, neurological checks, and periodic blood work, is part of living with the device for its lifetime, which is typically five to seven years before the battery needs replacing and the pump is surgically swapped out.

Children and adolescents present additional considerations. In a pediatric series, the cumulative surgical revision rate for intrathecal baclofen pumps reached nearly 12% within six months of implantation, reflecting the additional challenges of growing bodies, higher activity levels, and the difficulty of communicating symptoms in younger or non-verbal patients. Managing a pain pump in this population requires especially close surveillance and a low threshold for investigating any change in symptoms or behavior.